Disease Overview Hodgkin lymphoma (HL) is an uncommon B-cell lymphoid malignancy affecting 8570 new patients annually and representing ~10% of all lymphomas in the United States. Diagnosis HL is c...

PURPOSEThe need for an individualized management of indolent clinical forms in mantle cell lymphoma (MCL) is increasingly recognized. We hypothesized that a tailored treatment with ibrutinib in...

TO THE EDITOR:

Click on the article title to read more.

Coordinación : Dr. Francisco Javier Peñalver Estado: Nueva publicación 2024 DESCARGAR DOCUMENTO

Click on the article title to read more.

This Good Practice Paper provides recommendations for the baseline investigation, risk stratification and use of prophylactic interventions for patients with large B-cell lymphoma at risk of central...

Leukemia - Identification, risk factors, and clinical course of CNS relapse in DLBCL patients across 19 prospective phase 2 and 3 trials—a LYSA and GLA/ DSHNHL collaboration

Genmab and AbbVie.

Over 60% of relapsed/refractory (R/R) large B-cell lymphoma (LBCL) patients who receive chimeric antigen receptor (CAR) T cells will experience disease progression. There is no standard next line of...

Many therapies are available for the treatment of relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) after ≥ 2 lines of therapy, albeit with scant evidence on the comparative effective...

Click on the article title to read more.

The optimal treatment strategy for newly diagnosed primary central nervous system lymphoma (PCNSL) has yet to be established, especially in the elderly. In the current study, we conducted a phase II...

Key PointsCAR T-cell therapy demonstrates superior efficacy to bispecific antibody in DLBCL treatment, with higher CR rates.CAR T-cell therapy exhibits hig

Circulating tumour DNA (ctDNA) is the leading liquid biopsy approach in lymphomas. Our targeted next-generation sequencing panel detecting specific diffuse large B-cell lymphoma markers (mutations,...

In patients with mostly CD30-expressing peripheral T-cell lymphomas other than non-anaplastic large-cell lymphoma, CHEP–BV (with or without autologous HSCT) followed by brentuximab vedotin consolid...

Follicular lymphoma (FL) is the second most common histologic type of non-Hodgkin lymphoma diagnosed worldwide [1,2]. The disease is characterized by an indolent clinical behavior but is not curable...

AbstractPurpose:. This phase II clinical trial evaluated the combination of ibrutinib with rituximab, gemcitabine, and oxaliplatin (R-GemOx) in patients with nongerminal center B-cell–like (non-GCB)...

Crochet et al performed a retrospective analysis of the efficacy of chimeric antigen receptor (CAR) T-cell therapy for diffuse large B-cell lymphoma (DLBCL

Despite extensive efforts to improve the prognosis for people with peripheral T-cell lymphoma, patient outcomes are still disappointingly poor.1,2 This lack of improvement is especially striking when...

PURPOSENodular lymphocyte–predominant Hodgkin lymphoma (NLPHL) is a rare cancer, and large international cooperative efforts are needed to evaluate the significance of clinical risk factors and...

Given the significant limitations of available literature, central nervous system (CNS) prophylaxis in large B-cell lymphomas remains debatable. Wilson and colleagues provide cautious recommendatio...

Comparison of the 2007 EORTC/ISCL and the 2022 EORTC/ISCL/USCLC blood staging guidelines for cutaneous T-cell lymphoma at a single institution reveals the

The atezolizumab, venetoclax, and obinutuzumab triplet combination was shown to be active and safe, suggesting that this chemotherapy-free regimen could become a new first-line treatment approach in...

EHA Library; Abramson J. Jun 13 2024; 4136516;

Blood Cancer Journal - Comparative effectiveness of 6x R-CHOP21 versus 6x R-CHOP21 + 2 R for patients with advanced-stage diffuse large B-cell lymphoma

BACKGROUNDThe role of consolidation radiotherapy in primary mediastinal B-cell lymphoma (PMBCL) patients is controversial.METHODSThe IELSG37 trial, a randomized non-inferiority study, aimed to assess...

An abstract is unavailable.

Abstract. T-cell engaging–therapies have transformed the treatment landscape of relapsed and refractory B-cell non-Hodgkin lymphomas by offering highly eff

Mantle cell lymphoma is a rare subtype of B-cell Non-Hodgkin-lymphoma which is clinically characterized by its heterogeneous behaviour with courses ranging

Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma (CTCL). While MF generally follows an indolent course, a subset of patients will experience...

The manual of choice for doctors and practitioners involved in Hematopoietic Cell Transplantation (HCT) and Cellular Therapies.

Odronextamab, a CD20×CD3 bispecific antibody that engages cytotoxic T cells to destroy malignant B cells, has demonstrated encouraging activity across multiple subtypes of relapsed/refractory (R/R)...

Pirtobrutinib shows promising safety and activity among patients with Richter transformation, most of whom received previous Richter transformation-directed therapy, including covalent BTK inhibito...

Abstract. Purpose: Greater disease burden is a well-established predictor of poorer outcomes following chimeric antigen receptor T-cell therapy (CART). While bridging therapy (BT) is widely used...